

=====

Sequence Listing was accepted.

See attached Validation Report.

If you need help call the Patent Electronic Business Center at (866)
217-9197 (toll free).

Reviewer: Anne Corrigan

Timestamp: [year=2008; month=9; day=3; hr=16; min=58; sec=29; ms=888;]

=====

Application No: 10502328 Version No: 6.0

Input Set:**Output Set:**

Started: 2008-09-03 16:31:19.553
Finished: 2008-09-03 16:31:23.358
Elapsed: 0 hr(s) 0 min(s) 3 sec(s) 805 ms
Total Warnings: 29
Total Errors: 23
No. of SeqIDs Defined: 29
Actual SeqID Count: 29

Error code	Error Description
W 213	Artificial or Unknown found in <213> in SEQ ID (1)
W 213	Artificial or Unknown found in <213> in SEQ ID (2)
E 257	Invalid sequence data feature in <221> in SEQ ID (2)
W 213	Artificial or Unknown found in <213> in SEQ ID (3)
E 257	Invalid sequence data feature in <221> in SEQ ID (3)
E 257	Invalid sequence data feature in <221> in SEQ ID (3)
W 213	Artificial or Unknown found in <213> in SEQ ID (4)
W 213	Artificial or Unknown found in <213> in SEQ ID (5)
W 213	Artificial or Unknown found in <213> in SEQ ID (6)
W 213	Artificial or Unknown found in <213> in SEQ ID (7)
E 257	Invalid sequence data feature in <221> in SEQ ID (7)
W 213	Artificial or Unknown found in <213> in SEQ ID (8)
E 257	Invalid sequence data feature in <221> in SEQ ID (8)
W 213	Artificial or Unknown found in <213> in SEQ ID (9)
E 257	Invalid sequence data feature in <221> in SEQ ID (9)
W 213	Artificial or Unknown found in <213> in SEQ ID (10)
E 257	Invalid sequence data feature in <221> in SEQ ID (10)
W 213	Artificial or Unknown found in <213> in SEQ ID (11)
E 257	Invalid sequence data feature in <221> in SEQ ID (11)
W 213	Artificial or Unknown found in <213> in SEQ ID (12)

Input Set:

Output Set:

Started: 2008-09-03 16:31:19.553
Finished: 2008-09-03 16:31:23.358
Elapsed: 0 hr(s) 0 min(s) 3 sec(s) 805 ms
Total Warnings: 29
Total Errors: 23
No. of SeqIDs Defined: 29
Actual SeqID Count: 29

Error code	Error Description
E 257	Invalid sequence data feature in <221> in SEQ ID (12)
W 213	Artificial or Unknown found in <213> in SEQ ID (13)
E 257	Invalid sequence data feature in <221> in SEQ ID (13)
W 213	Artificial or Unknown found in <213> in SEQ ID (14)
E 257	Invalid sequence data feature in <221> in SEQ ID (14)
W 213	Artificial or Unknown found in <213> in SEQ ID (15)
E 257	Invalid sequence data feature in <221> in SEQ ID (15)
W 213	Artificial or Unknown found in <213> in SEQ ID (16)
E 257	Invalid sequence data feature in <221> in SEQ ID (16)
W 213	Artificial or Unknown found in <213> in SEQ ID (17)
E 257	Invalid sequence data feature in <221> in SEQ ID (17)
W 213	Artificial or Unknown found in <213> in SEQ ID (18)
W 213	Artificial or Unknown found in <213> in SEQ ID (19)
W 213	Artificial or Unknown found in <213> in SEQ ID (20) This error has occurred more than 20 times, will not be displayed
E 257	Invalid sequence data feature in <221> in SEQ ID (20)
E 257	Invalid sequence data feature in <221> in SEQ ID (21)
E 257	Invalid sequence data feature in <221> in SEQ ID (22)
E 257	Invalid sequence data feature in <221> in SEQ ID (23)
E 257	Invalid sequence data feature in <221> in SEQ ID (25)
E 257	Invalid sequence data feature in <221> in SEQ ID (26) This error has occurred more than 20 times, will not be displayed

SEQUENCE LISTING

<110> Zimmerman, Daniel H
 Charoenvit, Yupin
 Rosenthal, Kenneth
 Whelan, Mike

<120> METHODS FOR TREATING DISEASES OR CONDITIONS WITH PEPTIDE
 CONSTRUCTS

<130> CS-118

<140> 10502328
 <141> 2005-05-19

<150> US 60/350,032
 <151> 2002-01-23

<150> US 60/349,982
 <151> 2002-01-23

<150> US 60/349,983
 <151> 2002-01-23

<150> PCT/US03/01816
 <151> 2003-01-23

<160> 29

<170> PatentIn version 3.2

<210> 1
 <211> 15
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Completely synthesized peptide construct

<400> 1

Glu Lys Ala Gly Val Val Ser Thr Gly Leu Ile Gln Asn Gly Asp
 1 5 10 15

<210> 2
 <211> 15
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Completely synthesized peptide construct

<220>
 <221> MISC_FEATURE

<222> (1)..(1)
<223> acetyl, ClAc, BrAc

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> X is A or N and when X is A, then A is either cyclohexylalanine or D-alanine

<220>
<221> MISC_FEATURE
<222> (15)..(15)
<223> highly variable fragment wherein isoleucine at 143 and leucine at 159 in contact with CD4 phenylalanine as the 43 residue

<220>
<221> MOD_RES
<222> (15)..(15)
<223> AMIDATION

<400> 2

Xaa	Gly	Gln	Glu	Glu	Lys	Ala	Gly	Val	Val	Ser	Thr	Gly	Leu	Ile
1				5				10					15	

<210> 3
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Completely synthesized peptide construct

<220>
<221> MOD_RES
<222> (1)..(1)
<223> ACETYLATION, Aad

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> acetyl, ClAc, BrAc

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> X is A or E and when X is A, then A is either cyclohexylalanine or D-alanine

<220>
<221> MOD_RES
<222> (11)..(11)
<223> AMIDATION

<400> 3

Xaa Glu Thr Val Gly Val Ser Gln Leu Glu Val
1 5 10

<210> 4

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Completely synthesized peptide construct

<400> 4

Asn Gly Gln Glu Glu Thr Val Gly Val Ser Ser Thr Gln Leu Ile
1 5 10 15

<210> 5

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<223> Completely synthesized peptide construct

<400> 5

Asn Gly Gln Glu Glu Lys Ala Gly Val Val Ser Thr Gly Leu Ile Gly
1 5 10 15

Gly Gly

<210> 6

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Completely synthesized peptide construct

<220>

<221> MISC_FEATURE

<222> (1)..(1)

<223> cyclohexylalanine, D-alanine, acetyl, ClAc, BrAc

<220>

<221> MISC_FEATURE

<222> (1)..(1)

<223> Xaa is an amino acid V, L, I, G or A

<220>
<221> MISC_FEATURE
<222> (5)..(5)
<223> Xaa is an amino acid V, L, I, G or A

<220>
<221> MISC_FEATURE
<222> (7)..(7)
<223> Xaa is an amino acid V, L, I, G or A

<400> 6

Xaa Glu Glu Thr Xaa Gly Xaa Ser Gln Leu Glu Val Gly Gly Gly
1 5 10 15

<210> 7
<211> 18
<212> PRT
<213> Artificial Sequence

<220>
<223> Completely synthesized peptide construct

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> acetyl, ClAc, BrAc

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> X is A or D and when X is A, then A is either cyclohexylalanine or D-alanine

<220>
<221> MISC_FEATURE
<222> (6)..(6)
<223> Xaa is an amino acid V, L, I, G or A

<220>
<221> MOD_RES
<222> (18)..(18)
<223> AMIDATION

<400> 7

Xaa Gly Gln Glu Glu Xaa Ala Gly Val Val Ser Thr Gly Leu Ile Gly
1 5 10 15

Gly Gly

<210> 8
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> Completely synthesized peptide construct

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> acetyl, ClAc, BrAc

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> X is A or G and when X is A, then A is either cyclohexylalanine or D-alanine

<220>
<221> MOD_RES
<222> (17)..(17)
<223> AMIDATION

<400> 8

Xaa Gln Glu Glu Lys Ala Gly Val Val Ser Thr Gly Leu Ile Gly Gly
1 5 10 15

Gly

<210> 9
<211> 18
<212> PRT
<213> Artificial Sequence

<220>
<223> Completely synthesized peptide construct

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> acetyl, ClAc, BrAc

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> X is A or D and when X is A, then A is either cyclohexylalanine or D-alanine

<220>
<221> MISC_FEATURE
<222> (6)..(6)
<223> Xaa is an amino acid V, L, I, G, A

<220>
<221> MISC_FEATURE
<222> (6)..(6)
<223> analogues such as substituted epsilon amino (methyl, alkyl)
Lysine or hydroxy-Leucine or Leucine

<220>
<221> MOD_RES
<222> (18)..(18)
<223> AMIDATION

<400> 9

Xaa Gly Gln Glu Glu Xaa Ala Gly Val Val Ser Thr Gly Leu Ile Gly
1 5 10 15

Gly Gly

<210> 10
<211> 18
<212> PRT
<213> Artificial Sequence

<220>
<223> Completely synthesized peptide construct

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> acetyl, ClAc, BrAc

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> X is A or D and when X is A, then A is either cyclohexylalanine or D-alanine

<220>
<221> MOD_RES
<222> (18)..(18)
<223> AMIDATION

<400> 10

Xaa Gly Gln Glu Glu Phe Ala Gly Val Val Ser Thr Gly Leu Ile Gly
1 5 10 15

Gly Gly

<210> 11
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Completely synthesized peptide construct

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> acetyl, ClAc, BrAc

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> X is A or E and when X is A, then A is either cyclohexylalanine or D-alanine

<220>
<221> MOD_RES
<222> (10)..(10)
<223> AMIDATION

<400> 11

Xaa Thr Val Gly Val Ser Gln Leu Glu Val
1 5 10

<210> 12
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Completely synthesized peptide construct

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> acetyl, ClAc, BrAc

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> X is A or E and when X is A, then A is either cyclohexylalanine or D-alanine

<220>

<221> MOD_RES

<222> (10)..(10)

<223> AMIDATION

<400> 12

Xaa Thr Val Gly Val Ser Gln Leu Glu Val

1 5 10

<210> 13

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Completely synthesized peptide construct

<220>

<221> MISC_FEATURE

<222> (1)..(1)

<223> acetyl, ClAc, BrAc

<220>

<221> MISC_FEATURE

<222> (1)..(1)

<223> X is A or E and when X is A, then A is either cyclohexylalanine or D-alanine

<220>

<221> MOD_RES

<222> (9)..(9)

<223> AMIDATION

<400> 13

Xaa Thr Val Gly Val Ser Gln Leu Glu

1 5

<210> 14

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Completely synthesized peptide construct

<220>

<221> MISC_FEATURE

<222> (1)..(1)

<223> acetyl, ClAc, BrAc

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> X is A or E and when X is A, then A is either cyclohexylalanine or D-alanine

<220>
<221> MOD_RES
<222> (8)..(8)
<223> AMIDATION

<400> 14

Xaa Thr Val Gly Val Ser Gln Leu

1 5

<210> 15
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Completely synthesized peptide construct

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> acetyl, ClAc, BrAc

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> X is A or E and when X is A, then A is either cyclohexylalanine or D-alanine

<220>
<221> MOD_RES
<222> (7)..(7)
<223> AMIDATION

<400> 15

Xaa Thr Val Gly Val Ser Gln

1 5

<210> 16
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Completely synthesized peptide construct

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> acetyl, ClAc, BrAc

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> X is A or E and when X is A, then A is either cyclohexylalanine or D-alanine

<220>
<221> MOD_RES
<222> (6)..(6)
<223> AMIDATION

<400> 16

Xaa Thr Val Gly Val Ser
1 5

<210> 17
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Completely synthesized peptide construct

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> acetyl, ClAc, BrAc

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> X is A or E and when X is A, then A is either cyclohexylalanine or D-alanine

<220>
<221> MOD_RES
<222> (5)..(5)
<223> AMIDATION

<400> 17

Xaa Thr Val Gly Val
1 5

<210> 18
<211> 15

<212> PRT
 <213> Artificial Sequence

 <220>
 <223> Completely synthesized peptide construct

 <220>
 <221> MISC_FEATURE
 <222> (1)..(1)
 <223> acetyl, ClAc, BrAc

 <220>
 <221> MISC_FEATURE
 <222> (1)..(1)
 <223> X is A or D and when X is A, then A is either cyclohexylalanine or D-alanine

 <400> 18

Xaa	Gly	Gln	Glu	Glu	Lys	Ala	Gly	Val	Val	Ser	Thr	Gly	Leu	Ile
1				5				10					15	

<210> 19
 <211> 14
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Completely synthesized peptide construct

<220>
 <221> MISC_FEATURE
 <222> (1)..(1)
 <223> acetyl, ClAc, BrAc

<220>
 <221> MISC_FEATURE
 <222> (1)..(1)
 <223> X is A or G and when X is A, then A is either cyclohexylalanine or D-alanine

 <400> 19

Xaa	Gln	Glu	Glu	Lys	Ala	Gly	Val	Val	Ser	Thr	Gly	Leu	Ile
1				5				10					

<210> 20
 <211> 19
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Completely synthesized peptide construct

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> acetyl, ClAc, BrAc

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> X is A or D and when X is A, then A is either cyclohexylalanine or D-alanine

<220>
<221> MOD_RES
<222> (19)..(19)
<223> AMIDATION

<400> 20

Xaa Gly Gln Glu Glu Lys Ala Gly Gly Val Val Ser Thr Gly Leu Ile
1 5 10 15

Gly Gly Gly

<210> 21
<211> 18
<212> PRT
<213> Artificial Sequence

<220>
<223> Completely synthesized peptide construct

<220>
<221> MISC_FEATURE
<222> (8)..(8)
<223> X is gamma aminobutyric acid (gaba) or 3 amino propanoic acid (apa)

<220>
<221> MOD_RES
<222> (18)..(18)
<223> AMIDATION

<400> 21

Asp Gly Gln Glu Glu Lys Ala Xaa Val Val Ser Thr Gly Leu Ile Gly Gly
1 5 10 15

Gly

<210> 22
 <211> 17
 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> Completely synthesized peptide construct

 <220>
 <221> MISC_FEATURE
 <222> (1)..(1)
 <223> acetyl, ClAc, BrAc

 <220>
 <221> MISC_FEATURE
 <222> (1)..(1)
 <223> X is A or D and when X is A, then A is either cyclohexylalanine or D-alanine

 <220>
 <221> MISC_FEATURE
 <222> (5)..(5)
 <223> X is gamma aminobutyric acid (gaba) or 3 amino
 propanoic acid (apa)

 <220>
 <221> MOD_RES
 <222> (17)..(17)
 <223> AMIDATION

 <400> 22

Xaa Gly Gln Glu Xaa Ala Gly Val Val Ser Thr Gly Leu Ile Gly Gly Gly
 1 5 10 15

<210> 23
 <211> 16
 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> Completely synthesized peptide construct

 <220>
 <221> MISC_FEATURE
 <222> (1)..(1)
 <223> X is gamma aminobutyric acid (gaba) or 3 amino
 propanoic acid (apa)

 <220>
 <221> MISC_FEATURE
 <222> (1)..(1)
 <223> acetyl, ClAc, BrAc

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> X is A or E and when X is A, then A is either cyclohexylalanine or D-alanine

<220>
<221> MOD_RES
<222> (16)..(16)
<223> AMIDATION

<400> 23

Xaa Glu Glu Lys Ala Gly Val Val Ser Thr Gly Leu Ile Gly Gly Gly
1 5 10 15

<210> 24
<211> 26
<212> PRT
<213> Artificial Sequence

<220>
<223> Completely synthesized peptide construct

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> acetyl, ClAc, BrAc

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> X is A or N and when X is A, then A is either cyclohexylalanine or D-alanine

<400> 24

Xaa Gly Gln Glu Glu Lys Ala Gly Val Val Ser Thr Gly Leu Ile Gln
1 5 10 15

Asn Gly Asp Trp Thr Phe Gln Thr Leu Val
20 25

<210> 25
<211> 26
<212> PRT
<213> Artificial Sequence

<220>
<223> Completely synthesized peptide construct

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> acetyl, ClAc, BrAc

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> X is A or N and when X is A, then A is either cyclohexylalanine or D-alanine

<220>
<221> MOD_RES
<222> (26)..(26)
<223> AMIDATION

<400> 25

Xaa Gly Gln Glu Glu Lys Ala Gly Val Val Ser Thr Gly Leu Ile Gln
1 5 10 15

Asp Gly Asp Trp Thr Phe Gln Thr Leu Val
20 25

<210> 26
<211> 27
<212> PRT
<213> Artificial Sequence

<220>
<223> Completely synthesized peptide construct

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> acetyl, ClAc, BrAc

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> X is A or N and when X is A, then A is either cyclohexylalanine or D-alanine

<220>
<221> misc_feature
<222> (18)..(18)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> MISC_FEATURE
<222> (19)..(19)

<223> hydrophilic aminobutanoic acid (aba)

<220>

<221> MISC_FEATURE

<222> (19)..(19)

<223> S or not present

<220>

<221> MOD_RES

<222> (19)..(19)

<223> AMIDATION

<400> 26

Xaa Gly Gln Glu Glu Lys Ala Gly Val Val Ser Thr Gly Leu Ile Gln
1 5 10 15

Ala Xaa Gly Asp Trp Thr Phe Gln Thr Leu Val
20 25

<210> 27

<211> 22

<212> PRT

<213> Artificial Sequence

<220>

<223> Completely synthesized peptide construct

<220>

<221> MISC_FEATURE

<222> (1)..(1)

<223> acetyl, ClAc, BrAc

<220>

<221> MISC_FEATURE

<222> (1)..(1)

<223> X is A or E and when X is A, then A is either cyclohexylalanine or D-alanine

<220>

<221> MOD_RES

<222> (22)..(22)

<223> AMIDATION

<400> 27

Xaa Lys Ala Gly Val Val Ser Thr Gly Leu Ile Gln Asn Gly Asp Trp
1 5 10 15

Thr Phe Gln Thr Leu Val
20

<210> 28
 <211> 19
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Completely synthesized peptide construct

<220>
 <221> MISC_FEATURE
 <222> (1)..(1)
 <223> acetyl, ClAc, BrAc

<220>
 <221> MISC_FEATURE
 <222> (1)..(1)
 <223> X is A or G and when X is A, then A is either cyclohexylalanine or D-alanine

<220>
 <221> MISC_FEATURE
 <222> (12)..(12)
 <223> X is gamma aminobutyric acid (gaba) or 3 amino propanoic acid (apa)

<220>
 <221> MOD_RES
 <222> (19)..(19)
 <223> AMIDATION

<400> 28

Xaa Gly Gly Gly Ile Leu Gly Thr Ser Val Val Xaa Ala Lys Glu Glu Gln Gly
 1 5 10 15

Asp

<210> 29
 <211> 5
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Completely synthesized peptide construct

<220>
 <221> MISC_FEATURE
 <222> (1)..(1)
 <223> acetyl, ClAc, BrAc

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> X is A or G and when X is A, then A is either cyclohexylalanine or D-alanine

<220>
<221> MOD_RES
<222> (4)..(4)
<223> AMIDATION

<400> 29

Xaa Val Ala Lys Glu
1 5